Aldose reductase inhibition suppresses the expression of Th2 cytokines and airway inflammation in ovalbumin-induced asthma in mice

Journal of Immunology

Volumn 183, Issue 7, 2009, Pages 4723-4732

  Yadav, Umesh C S ^a   Naura, Amarjit S ^c   Aguilera Aguirre, Leopoldo ^b   Ramana, Kota V ^a   Boldogh, Istvan ^b   Sur, Sanjiv ^a,b   Boulares, Hamid A ^c   Srivastava, Satish K ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; CYTOKINE; FIDARESTAT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; OVALBUMIN; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; SORBINIL; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; ZOPOLRESTAT; AUTACOID;

AIRWAY; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTHMA; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME INHIBITION; EOSINOPHIL; EPITHELIUM CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RESPIRATORY TRACT INFLAMMATION; TH2 CELL; ANIMAL; BIOSYNTHESIS; BRONCHUS; C57BL MOUSE; CELL CULTURE; CHICKEN; CYTOTOXICITY; DRUG ANTAGONISM; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; RESPIRATORY TRACT MUCOSA; SIGNAL TRANSDUCTION;

ALDEHYDE REDUCTASE; ANIMALS; ASTHMA; BRONCHI; CELLS, CULTURED; CHICKENS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION MEDIATORS; MICE; MICE, INBRED C57BL; OVALBUMIN; RESPIRATORY MUCOSA; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TH2 CELLS;

EID: 70449719352     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901177     Document Type: Article

References (66)

1. Holgate, S. T. 2008. The airway epithelium is central to the pathogenesis of asthma. Allergol. Int. 57: 1-10.
2. Barnes, P. J. 1990. Reactive oxygen species and airway inflammation. Free Radical Biol. Med. 9: 235-243. (Pubitemid 20325581)
3. Henricks, P. A., and F. P. Nijkamp. 2001. Reactive oxygen species as mediators in asthma. Pulm. Pharmacol. Ther. 14: 409-420.
4. Levine, S. J. 1995. Bronchial epithelial cell-cytokine interactions in airway epithelium. J. Invest. Med. 43: 241-249.
5. Kips, J. C. 2001. Cytokine in asthma. Eur. Respir. J. Suppl. 34: 24s-33s.
6. Fireman, P. 2003. Understanding asthma pathophysiology. Allergy Asthma Proc. 24: 79-83.
7. Bloemen, K., S. Verstraelen, R. Van Den Heuvel, H. Witters, I. Nelissen, and G. Schoeters. 2007. The allergic cascade: review of the most important molecules in the asthmatic lung. Immunol. Lett. 113: 6-18.
8. Sheppard, D. 2009. Adhesion molecules in asthma and airway diseases. In Asthma and COPD, 2nd ed. P. Barnes, J. Drazen, S. Rennard, and N. Thomson, eds. Academic Press, Oxford, pp. 257-263.
9. Fujisawa, T. 2005. Role of oxygen radicals on bronchial asthma. Curr. Drug. Targets Inflamm. Allergy 4: 505-509. (Pubitemid 41052418)
10. Rahman, I., S. K. Biswas, and A. Kode. 2006. Oxidant and antioxidant balance in the airways and airway diseases. Eur. J. Pharmacol. 533: 222-239. (Pubitemid 43340015)
11. Mak, J. C., and M. M. Chan-Yeung. 2006. Reactive oxidant species in asthma. Curr. Opin. Pulm. Med. 12: 7-11.
12. Koay, M. A., X. Gao, M. K. Washington, K. S. Parman, R. T. Sadikot, T. S. Blackwell, and J. W. Christman. 2002. Macrophages are necessary for maximal nuclear factor-κB activation in response to endotoxin. Am. J. Respir. Cell Mol. Biol. 26: 572-578.
13. Ndengele, M. M., C. Muscoli, Z. Q. Wang, T. M. Doyle, G. M. Matuschak, and D. Salvemini. 2005. Superoxide potentiates NF-κB activation and modulates endotoxin-induced cytokine production in alveolar macrophages. Shock 23: 186-193.
14. Poynter, M. E., C. G. Irvin, and Y. M. Janssen-Heininger. 2003. A prominent role for airway epithelial NF-κB activation in lipopolysaccharide-induced airway inflammation. J. Immunol. 170: 6257-6265. (Pubitemid 36682611)
15. Cheng, D. S., W. Han, S. M. Chen, T. P. Sherrill, M. Chont, G. Y. Park, J. R. Sheller, V. V. Polosukhin, J. W. Christman, F. E. Yull, and T. S. Blackwell. 2007. Airway epithelium controls lung inflammation and injury through the NF-κB pathway. J. Immunol. 178: 6504-6513.
16. Hart, L. A., V. L. Krishnan, I. M. Adcock, P. J. Barnes, and K. F. Chung. 1998. Activation and localization of transcription factor, nuclear factor-κB, in asthma. Am. J. Respir. Crit. Care Med. 158: 1585-1592.
17. Page, K., J. Li, L. Zhou, S. Iasvovskaia, K. C. Corbit, J. W. Soh, I. B. Weinstein, A. R. Brasier, A. Lin, and M. B. Hershenson. 2003. Regulation of airway epithelial cell NF-κB-dependent gene expression by protein kinase C δ. J. Immunol. 170: 5681-5689. (Pubitemid 36617861)
18. Hoffmann, A., and D. Baltimore. 2006. Circuitry of nuclear factor-κB signaling. Immunol. Rev. 210: 171-186.
19. Cembrzynska-Norvak, M. E., A. D. Szklarz, and J. A. Teodorczyk-Injeyan. 1993. Elevated release of TNF-α and interferon-γ by bronchoalveolar leukocytes from patients with bronchial asthma. Am. Rev. Respir. Dis. 147: 291-295.
20. Gosset, P., I. Tillie Leblond, A. Janin, C. H. Marquette, M. C. Copin, B. Wallaert, and A. B. Tonnel. 1995. Expression of E-selectin, ICAM-1 and VCAM-1 on bronchial biopsies from allergic and non-allergic asthmatic patients. Int. Arch. Allergy Appl. Immunol. 106: 69-77.
21. Hallsworth, M. P., C. P. C. Soh, S. J. Lane, J. P. Arm, and T. H. Lee. 1994. Selective enhancement of GM-CSF, TNF-α, IL-1β and IL-8 production by monocytes and macrophages of asthmatic subjects. Eur. Respir. J. 7: 1096-1102.
22. Sousa, A. R., S. J. Lane, J. A. Nakhosteen, T. Yoshimura, T. H. Lee, and R. N. Poston. 1994. Increased expression of the monocyte chemoattractant protein-1 in bronchial tissues from asthmatic subjects. Am. J. Respir. Cell Mol. Biol. 10: 142-147.
23. Sousa, A. R., R. N. Poston, S. J. Lane, J. A. Narhosteen, and T. H. Lee. 1993. Detection of GM-CSF in asthmatic bronchial epithelium and decrease by inhaled corticosteroids. Am. Rev. Respir. Dis. 147: 1557-1561.
24. 2 concentrations and cyclooxygenase-2 expression in asthmatic subjects with sputum eosinophilia. J. Allergy Clin. Immunol. 112: 709-716.
25. Hamid, Q., D. R. Springall, V. Riveros-Moreno, P. Chanez, P. Howarth, A. Redington, J. Bousquet, P. Godard, S. Holgate, and J. M. Polak. 1993. Induction of nitric oxide synthase in asthma. Lancet 342: 1510-1514. (Pubitemid 23362167)
26. Duan, W., J. H. Chan, C. H. Wong, B. P. Leung, and W. S. Wong. 2004. Anti-inflammatory effects of mitogen-activated protein kinase kinase inhibitor U0126 in an asthma mouse model. J. Immunol. 172: 7053-7059. (Pubitemid 38669147)
27. Duan, W., A. M. Aguinaldo Datiles, B. P. Leung, C. J. Vlahos, and W. S. Wong. 2005. An anti-inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model. Int. Immunopharmacol. 5: 495-502. (Pubitemid 40430757)
28. Bao, Z., S. Lim, W. Liao, Y. Lin, C. Thiemermann, B. P. Leung, and W. S. Wong. 2007. Glycogen synthase kinase-3β inhibition attenuates asthma in mice. Am. J. Respir. Crit. Care Med. 176: 431-438. (Pubitemid 47358096)
29. Duan, W., J. H. Chan, K. McKay, J. R. Crosby, H. H. Choo, B. P. Leung, J. G. Karras, and W. S. Wong. 2005. Inhaled p38α mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am. J. Respir. Crit. Care Med. 171: 571-578. (Pubitemid 40365411)
30. Henderson, W. R., Jr., E. Y. Chi, J. L. Teo, C. Nguyen, and M. Kahn. 2002. A small molecule inhibitor of redox-regulated NF-κB and activator protein-1 transcription blocks allergic airway inflammation in a mouse asthma model. J. Immunol. 169: 5294-5299.
31. Chue, S. C., C. J. Seow, W. Duan, K. S. Yeo, A. H. Koh, and W. S. Wong. 2004. Inhibitor of p42/44 mitogen-activated protein kinase, but not p38 MAPK, attenuated antigen challenge of guinea pig airways in vitro. Int. Immunopharmacol. 4: 1089-1098.
32. Desmet, C., P. Gosset, B. Pajak, D. Cataldo, M. Bentires-Alj, P. Lekeux, and F. Bureau. 2004. Selective blockade of NF-κB activity in airway immune cells inhibits the effector phase of experimental asthma. J. Immunol. 173: 5766-5775.
33. Leckie, M. J., A. Brinke, J. Khan, Z. Diamant, B. J. O'Connor, C. M. Walls, A. K. Mathur, H. C. Cowley, K. F. Chung, R. Djukanovic, et al. 2000. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 356: 2144-2148.
34. Yang, G., L. Li, A. Volk, E. Emmell, T. Petley, J. Giles-Komar, P. Rafferty, M. Lakshminarayanan, D. E. Griswold, P. J. Bugelski, and A. M. Das. 2005. Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice. J. Pharmacol. Exp. Ther. 313: 8-15.
35. Cheng, G., M. Arima, K. Honda, H. Hirata, F. Eda, N. Yoshida, F. Fukushima, Y. Ishii, and T. Fukuda. 2002. Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyper-reactivity in mouse asthma model. Am. J. Respir. Crit. Care Med. 166: 409-416.
36. Ramana, K. V., B. Friedrich, S. Srivastava, A. Bhatnagar, and S. K. Srivastava. 2004. Activation of nulcear factor-κB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes 53: 2910-2920.
37. Ramana, K. V., A. Bhatnagar, and S. K. Srivastava. 2004. Aldose reductase regulates TNF-α-induced cell signaling and apoptosis in vascular endothelial cells. FEBS Lett. 570: 189-194.
38. Pladzyk, A., A. B. Reddy, U. C. Yadav, R. Tammali, K. V. Ramana, and S. K. Srivastava. 2006. Inhibition of aldose reductase prevents lipopolysaccharide-induced inflammatory response in human lens epithelial cells. Invest. Ophthalmol. Visual Sci. 47: 5395-5403. (Pubitemid 46723790)
39. Ramana, K. V., A. A. Fadl, R. Tammali, A. B. Reddy, A. K. Chopra, and S. K. Srivastava. 2006. Aldose reductase mediates the lipopolysaccharide-induced release of inflammatory mediators in RAW264.7 murine macrophages. J. Biol. Chem. 281: 33019-33029.
40. 2 mediation. Am. J. Physiol. 293: H3096-H3104.
41. Srivastava, S. K., K. V. Ramana, and A. Bhatnagar. 2005. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocrinol. Rev. 26: 380-392.
42. Ramana, K. V., B. L. Dixit, S. Srivastava, G. K. Balendiran, S. K. Srivastava, and A. Bhatnagar. 2000. Selective recognition of glutathiolated aldehydes by aldose reductase. Biochemistry 39: 12172-12180.
43. Williams, L. M., F. Lali, K. Willetts, C. Balague, N. Godessart, F. Brennan, M. Feldmann, and B. M. Foxwell. 2008. Rac mediates TNF-induced cytokine production via modulation of NF-κB. Mol. Immunol. 45: 2446-2454.
44. Khair, O. A., R. J. Davies, and J. L. Devalia. 1996. Bacterial-induced release of inflammatory mediators by bronchial epithelial cells. Eur. Respir. J. 9: 1913-1922.
45. Doganci, A., K. Sauer, R. Karwot, and S. Finotto. 2005. Pathological role of IL-6 in the experimental allergic bronchial asthma in mice. Clin. Rev. Allergy Immunol. 28: 257-269. (Pubitemid 41208915)
46. Masoli, M., D. Fabian, S. Holt, and R. Beasley. 2004. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59: 469-478.
47. CDC National Center for Health Statistics. Asthma prevalence, health care use and mortality: 2002. U.S. Department of Health and Human Services. Atlanta, GA. Available at: http://www.cdc.gov/nchs/products/pubs/pubd/hestats/ashtma03- 05/asthma03-05.htm#fig1.
48. National Heart, Lung, and Blood Institute Data Fact Sheet. 1999. Asthma Statistics, U. S. Department of Health and Human Services. National Institutes of Health. Available at: http://www.nhlbi.nih.gov/health/prof/lung/asthma/ asthstat.pdf.
49. Kamble, S., and M. J. Bharmal. 2009. Incremental direct expenditure of treating asthma in the U.S. J. Asthma. 46: 73-80.
50. Kirkham, P., and I. Rahman. 2006. Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. Pharmacol. Ther. 111: 476-494.
51. Schwartz, J., and S. T. Weiss. 1994. Relationship between dietary vitamin C intake and pulmonary function in the First National Health and Nutrition Examination Survey (NHANES I). Am. J. Clin. Nutr. 59: 110-114. (Pubitemid 24021718)
52. Dekhuijzen, P. N. 2004. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur. Respir. J. 23: 629-636.
53. De Benedetto, F., A. Aceto, B. Dragani, A. Spacone, S. Formisano, R. Pela, C. F. Donner, and C. M. Sanguinetti. 2005. Long-term oral n-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD. Pulm. Pharmacol. Ther. 18: 41-47.
54. Pela, R., A. M. Calcagni, S. Subiaco, P. Isidori, A. Tubaldi, and C. M. Sanguinetti. 1999. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration 66: 495-500.
55. Dekhuijzen, P. N., and W. J. van Beurden. 2006. The role for N-acetylcysteine in the management of COPD. Int. J. Chron. Obstruct. Pulm. Dis. 1: 99-106.
56. Ciencewicki, J., S. Trivedi, and S. R. Kleeberger. 2008. Oxidants and the pathogenesis of lung diseases. J. Allergy Clin. Immunol. 122: 456-468.
57. Antoniu, S. A. 2009. Daclizumab a novel corticosteroid-sparing therapy for asthma? Expert. Opin. Invest. Drugs 18: 369-371.
58. Busse, W. W., E. Israel, H. S. Nelson, J. W. Baker, B. L. Charous, D. Y. Young, V. Vexler, and R. S. Shames. 2008. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am. J. Respir. Crit. Care Med. 178: 1002-1008.
59. Perng, D. W., H. Y. Huang, Y. C. Lee, and P. R. Perng. 2004. Leukotriene modifier vs inhaled corticosteroid in mild-to-moderate asthma: clinical and anti-inflammatory effects. Chest 125: 1693-1699.
60. Redington, A. E., Q. H. Meng, D. R. Springall, T. J. Evans, C. Créminon, J. Maclouf, S. T. Holgate, P. H. Howarth, and J. M. Polak. 2001. Increased expression of inducible nitric oxide synthase and cyclo-oxygenase-2 in the airway epithelium of asthmatic subjects and regulation by corticosteroid treatment. Thorax 56: 351-357.
61. Temelkovski, J., S. P. Hogan, D. P. Shepherd, P. S. Foster, and R. K. Kumar. 1998. An improved murine model of asthma: selective airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen. Thorax 53: 849-856.
62. Kips, J. C. 2001. Cytokines in asthma. Eur. Respir. J. 34: 24s-33s.
63. Zhou, Y., M. McLane, and R. C. Levitt. 2001. Th2 cytokines and asthma: interleukin-9 as a therapeutic target for asthma. Resp. Res. 2: 80-84.
64. Koulis, A., and D. S. Robinson. 2000. The anti-inflammatory effects of interleukin-10 in allergic disease. Clin. Exp. Allergy 30: 747-750.
65. Tang, C., M. D. Inman, N. van Rooijen, P. Yang, H. Shen, K. Matsumoto, and P. M. O'Byrne. 2001. Th type-1-stimulating activity of lung macrophages inhibits Th2-mediated allergic airway inflammation by an IFN-γ-dependent mechanism. J. Immunol. 166: 1471-1481.
66. Gajewski, T. F., and F. W. Fitch. 1988. Anti-proliferative effect of IFN-γ in immune regulation, I: IFN-γ inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J. Immunol. 140: 4245-4252.